New use of rosiglitazone decreased following publication of a meta-analysis suggesting harm

Diabetic Medicine

Volumn 25, Issue 7, 2008, Pages 871-874

  Shah, B R ^a,b,c   Juurlink, D N ^a,b,c   Austin, P C ^a,d   Mamdani, M M ^a,e  

^a INSTITUTE FOR CLINICAL EVALUATIVE SCIENCES   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

Knowledge translation; Meta analysis; Pharmacoepidemiology; Prescribing practices; Rosiglitazone

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; GLIBENCLAMIDE; INSULIN; METFORMIN; PIOGLITAZONE; PROTON PUMP INHIBITOR; ROSIGLITAZONE; ANTIDIABETIC AGENT;

ARTICLE; CANADA; CONTROLLED STUDY; DATA ANALYSIS; DIABETES MELLITUS; DRUG SAFETY; DRUG UTILIZATION; GLYCEMIC CONTROL; META ANALYSIS; PRESCRIPTION; PUBLICATION; AGED; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS;

AGED; AGED, 80 AND OVER; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; META-ANALYSIS AS TOPIC; THIAZOLIDINEDIONES;

EID: 49649094094     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2008.02462.x     Document Type: Article

References (16)

1. Lamas GA, Pfeffer MA, Hamm P, Wertheimer J, Rouleau JL, Braun-wald E. Do the results of randomized clinical trials of cardiovascular drugs influence medical practice? The SAVE Investigators. New Engl J Med 1992; 327: 241-247.
2. Jackevicius CA, Anderson GM, Leiter L, Tu JV. Use of the statins in patients after acute myocardial infarction: does evidence change practice? Arch Intern Med 2001; 161: 183-188.
3. Austin PC, Mamdani MM, Tu K, Jaakkimainen L. Prescriptions for estrogen replacement therapy in Ontario before and after publication of the Women's Health Initiative study. J Am Med Assoc 2003; 289: 3241-3242.
4. Juurlink DN, Mamdani MM, Lee DS, Kopp A, Austin PC, Laupacis A et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. New Engl J Med 2004; 351: 543-551.
5. Austin PC, Mamdani MM. Impact of the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22/Reversal of Atherosclerosis With Aggressive Lipid Lowering trials on trends in intensive versus moderate statin therapy in Ontario, Canada. Circulation 2005; 112: 1296-1300.
6. Borzak S, Ridker PM. Discordance between meta-analyses and largescale randomized, controlled trials: examples from the management of acute myocardial infarction. Ann Intern Med 1995; 123: 873 -877.
7. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. New Engl J Med 2007; 356: 2457-2471.
8. Levy AR, O'Brien BJ, Sellors C, Grootendorst P, Willison D. Coding accuracy of administrative drug claims in the Ontario Drug Benefit database. Can J Clin Pharmacol 2003; 10: 67-71.
9. Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules I et al. Secondary prevention of macrovascular events in patients with Type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005; 366: 1279-1289.
10. Home PD, Pocock SJ, Beck-Nielsen H, Gomis R, Hanefeld M, Jones NP et al. Rosiglitazone evaluated for cardiovascular outcomes-interim analysis. New Engl J Med 2007; 357: 28-38.
11. Food and Drug Administration. FDA briefing document: joint meeting of the Endocrinologic and Metabolic Drug Advisory Committee and the Drug Safety and Risk Management Advisory Committee. Available at http://www.fda.gov/ohrms/ dockets/ac/07/briefing/2007-4308b1-02-fda-backgrounder.pdf Last accessed 1 March 2008.
12. Lincoff AM, Wolski K, Nicholls SJ, Nissen SE. Pioglitazone and risk of cardiovascular events in patients with Type 2 diabetes mellitus: a meta-analysis of randomized trials. J Am Med Assoc 2007; 298: 1180-1188.
13. Singh S, Loke YK, Furberg CD. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. J Am Med Assoc 2007; 298: 1189-1195.
14. Lipscombe LL, Gomes T, Levesque LE, Hux JE, Juurlink DN, Alter DA et al. Thiazolidinediones and cardiovascular outcomes in older patients with diabetes. J Am Med Assoc 2007; 298: 2634-2643.
15. Hux JE, Ivis F, Flintoft V, Bica A. Diabetes in Ontario: determination of prevalence and incidence using a validated administrative data algorithm. Diabetes Care 2002; 25: 512-516.
16. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. J Am Med Assoc 2002; 288: 321-333.